Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis Background: Addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy improves response rates and survival in patients with B-cell non-Hodgkin lymphoma (NHL). However, rituximab induces a transient B-cell depletion and a dose-dependent T-cell inactivation that could impair T-cell immunosurveillance. The impact of rituximab on second primary malignancy (SPM) risk remains unclear so far. We thus carried out a systematic review to compare SPM risk among patients treated or not with rituximab.
introduction Non-Hodgkin lymphoma (NHL) is one of the leading causes of cancer death in the USA [1] . The mortality rate associated with NHL in Europe reaches 30.4 by 100 000 persons (https://www. iarc.fr/en/media-centre/iarcnews/pdf/Ferlay%20J_EJC_2013. pdf ). The standard of care for patients with NHL now includes a chimeric anti-CD20 monoclonal, rituximab [2] . Rituximab (Rituxan, Genentech, Inc., South San Francisco, CA, USA; Mabthera, Roche, Switzerland) causes B-cell death after targeting the CD20 surface protein by a variety of mechanisms that rely mainly on antibody-dependent cell-mediated cytotoxicity and complement-dependent [3] . It is effective in B-cell malignancies, both as a single agent and in combination with chemotherapy (R-chemo) [3] . Adding rituximab to CHOP regimen and many other multiagent chemotherapy regimens has significantly improved treatment outcomes in a way that immunochemotherapy is now considered the new standard of care for this group of patients, irrespective of age and of lymphoma subtypes. Prolonged overall survival (OS) with R-chemo is reported in randomized trials in aggressive lymphomas such as diffuse large B-cell lymphoma (DLBCL) [2, 4] and Burkitt lymphoma [5] , as well as in indolent lymphomas as reported in a metaanalysis of six randomized trials of follicular lymphoma (FL) [6] . In marginal zone lymphoma (MZL) benefit is demonstrated mainly on disease control but not in OS [7] . In mantle cell lymphoma (MCL), a benefit on OS is observed in a retrospective analysis of patients older than 65 years [8] . Moreover, the benefit of rituximab has been demonstrated in maintenance therapy in FL and MCL. It increases progression-free survival (PFS) in patients with FL responding to an induction of immunochemotherapy [9] and OS in patients with MCL ineligible for high-dose therapy (HDT) followed by autologous stem cell transplantation [10] .
Rituximab administration results in profound normal B-cell depletion for several months [11] . Increased risk of infections, mainly viral, has been reported as well as secondary hypogammaglobulinemia [3] . These infections are mainly T-cell dependent and include hepatitis B virus reactivation, pneumocystis jirovecii pneumonia and John Cunningham virus (JCV) reactivation, the latter being associated with progressive multifocal leukoencephalopathy [3] . It has been proposed that this risk may occur through a B-cell depletion caused by rituximab that reduces the antigen presentation leading to T-cell inactivation [12] . Direct binding and toxicity of rituximab to a CD20 dim T-cell population may also contribute to the decreased T-cell activation [12] . T cells are further considered pivotal in cancer immunosurveillance [13] . Moreover, activation of T and B cells leads to the production of additional cytokines that further promote activation of innate immunity and support the expansion and production of tumor-specific T cells and antibodies, respectively, in order to control tumor promotion [14] .
Since prolonged survival rates are achieved with rituximab in B-cell NHL and rituximab may impair T-cell immunosurveillance, risk of second primary malignancies (SPMs) warrants long-term follow-up of survivors. Risk for SPM in NHL survivors has been studied in a meta-analysis of 19 trials [15] . Pooled relative risk for SPM occurrence was 1.88 (95% CI 1.58-2.22) which therefore constitutes a statistically significant increased risk compared with general population [15] . However, this analysis did not evaluate the specific contribution of rituximab.
We conducted a systematic review and meta-analysis of randomized, controlled trials in which NHL patients were randomly assigned to receive treatment different only from rituximab randomization. The aim of this study was to analyze the risk of SPM associated with rituximab. The contribution of clinical and histological characteristics as well as rituximab maintenance was also addressed.
methods search strategy
We carried out the systematic review of published literature by using the PubMed and EMBASE databases. PubMed search was realized through the website of the National Center for Biotechnology Information (U.S. National Library of Medicine) on 22 October 2013. We selected all randomized, controlled trials and clinical phase III trials with 'rituximab' in the 'supplementary concept' field in order to retrieve all rituximab synonyms. We further combined these results with studies having 'lymphoma' anywhere in the 'text word'. Publications in language other than English were excluded. The text word and MeSH/EMTREE terms rituximab and lymphoma were used for EMBASE search. The search was further limited to randomized, controlled trials. Searches were carried out on 10 September 2013 for EMBASE. Bibliographic references of relevant trials were also reviewed. Updated follow-up of trials included in our final analysis published as meeting proceedings of the American Society of Hematology and the American Society of Clinical Oncology from 1998 to 2013 were included as well.
selection criteria
We selected randomized, controlled trials that studied patients who had histologically proven NHL, including DLBCL, FL, MCL or MZL, and that (i) consisted of randomization arms that differed only from rituximab administration; (ii) addressed firstline or relapse/progression status; (iii) reported explicitly the SPM occurrence or related death and (iv) constituted an original publication. Secondary analysis (subset analysis, prognostic studies, quality of life or economic evaluation) were excluded in favor of the original publication. If SPM occurrence or related death were explicitly reported in a publication, but not relative to rituximab administration, authors were contacted for data. We included data of the selected trials from full-text articles and abstracts and the most recent data of the updated trials. We contacted the first authors of the included studies to obtain unreported data. We excluded chronic lymphocytic leukemia and small lymphocytic leukemia because of their intrinsic increased risk of SPM that warrants a separate analysis [16] . HIV patients were excluded for the same consideration [17] .
study selection, quality assessment and data extraction reviewers independently extracted the data and assessed the quality of articles. Disagreements between the two reviewers were resolved by a second common and consensual reviewing of those publications. The data extraction form was predefined and consisted of the publication reference, the beginning and the ending year of the trial, the histology, the chemotherapy regimen and the rituximab administration [whether rituximab was used in first or second line or in maintenance, its dosing (mg/m 2 ), the number of cycles, the schedule of administration, and the total duration of maintenance]. All events were recorded as well as the median follow-up. The following information was recorded for each treatment arm: number of enrolled patients, median age, female/male ratio, number of events, SPM occurrence (solid and hematological distinctly) and survival data.
statistical analysis
Since we carried out the meta-analysis on previously published data while no individual patient data were available, only the observed counts of events were analyzed. We thus estimated the individual odds ratios (OR), then the summary OR of SPM in patients allocated to rituximab-based arm when compared with the others, based on a random effects meta-analysis model [18] . Past rituximab therapy was allowed as long as identical in both trial arms and taken into account by the summary effect.
The Woolf's test for heterogeneity was computed. Descriptive statistics, namely percentages, median with interquartile range (IQR), are reported. Analysis was carried out on the R 3.0.2 software (http://www.R-project.org/).
results trials selection
Among the 314 randomized NHL trials initially retrieved, we identified 47 duplicates. Thus, 267 abstracts were screened. Thirtyfive of these abstracts were further assessed for eligibility through full-text analysis. Twenty-four original publications where first selected on the basis that treatment arms differed only from rituximab randomization and that they studied patients with the B-cell NHL subtypes previously described in a first-line or relapse/progression setting.
These 24 publications were then assessed for SPM occurrence or related death according to rituximab treatment. Nine trials were finally selected for analysis: RICOVER60 [19] , PRIMA [9] , MINT [4] , LNH 98.5 [20] , EORTC20981 [21] , IESLG-19 [7] , CORAL [22] , OSHO#39 [23] and SAKK35/98 [24] . The flow chart of the systematic review is presented in Figure 1 . SPM incidence according to rituximab treatment was explicit in five publications (RICOVER60, LNH98.5, PRIMA, EORTC20981, reviews CORAL). Detailed rituximab administration for the SPM reported in four publications were obtained by contacting authors who also provided updated data on SPM occurrence and survivals (IELSG19, OSHO#39, SAKK35/98, MINT). One trial was updated in a conference after publication [25] . Statistical analysis was carried out on an intention-to-treat basis in all but one trial [7] .
description of the selected trials These 9 trials cumulate 4621 patients, 2312 randomized to rituximab and 2309 not. These 9 trials are described in more detail in Table 1 . Histologies were DLBCL (n = 4 corresponding to 2686 patients), FL (n = 4 corresponding to 1704 patients) and extranodal MZL (MALT lymphoma) (n = 1 corresponding to 231 patients). In all trials but one [24] , patients were exposed to rituximab in combination with chemotherapy: CHOP, CHOEP, FCM, MCP, DHAP, ICE or chlorambucil. Trial SAKK35/98 addressed patients with FL and compared induction therapy with once per week for 4 weeks rituximab alone versus the same induction followed by four cycles of rituximab every 2 months [24] . Rituximab dosage was 375 mg/m 2 per cycle for all trials. Rituximab administration in each of the nine trials selected is described in Table 2 .
history of neoplasms in the inclusion criteria
Three trials (MINT, EORTC20981, OSHO#39) had no eligibility restrictions regarding past history of cancer. Two trials (IELSG19, RICOVER60) excluded patients with a previous diagnosis of malignancy. Three trials (LNH98.5, SAKK35/98, CORAL) excluded patients with a previous history of active cancer during the 5 previous years, but one of them (CORAL) allowed nonmelanoma skin cancer and in situ cervical cancer. One trial (PRIMA) excluded patients with previous history of cancer apart from adequately treated nonmelanoma skin cancer or in situ cervical cancer.
quantitative assessment of SPMs
At a median follow-up of 73 months [IQR: 72-84], a total of 334 SPMs was observed and reported in the 9 selected trials, including 169 SPMs in patients randomized to rituximab when compared with 165 SPMs in patients not randomized to rituximab (OR = 0.88; 95% CI 0.66-1.19). This represents an incidence of 7.3% (169/2312) of the patients randomized to R and 7.1% (165/2309) of the patients not randomized to R.
qualitative description of SPM subtypes
Description of SPM subtypes was retrieved in seven trials as shown in Table 3 . Forty-one SPM subtype could not be retrieved in the following three trials: EORTC20981, SAKK35/98, LNH98.5. The following description corresponds to the 293 malignancies subtypes that occurred among 280 patients.
Hematological SPM subtypes consisted of myelodysplasia, leukemia, monoclonal gammopathy of uncertain significance, multiple myeloma, plasmocytoma, myeloproliferative neoplasms, marginal zone and Hodgkin lymphomas. A total of 52 hematological SPMs were reported. Among them 24 occurred in patients randomized to R, and 28 in patients not randomized to R. 
analyses of the clinical characteristics and the rituximab administration in respect to SPMs
The median follow-up was 73 months [IQR: 72-84]. SPM occurrence and outcomes are summarized in Table 3 .
There was no evidence of any association between the allocation to rituximab and the occurrence of SPM (summary odds ratio = 1.05; 95% CI 0.84-1.32), with no heterogeneity across trials (P = 0.92). Figure 2 shows the corresponding meta-analysis plot of the effect of rituximab on the prevalence of SPM, where the confidence interval for each study is given by a horizontal line and the point estimate is given by a square whose height is inversely proportional to the standard error of the estimate. The summary odds ratio is shown as a diamond with horizontal limits at the confidence limits and width inversely proportional to its standard error.
Notably, the proportion of females, histology subtypes, use of rituximab in first line and use of rituximab over prolonged periods in maintenance did not influence SPM risk (P = 0.94, P = 0.80, P = 0.87, P = 0.87, respectively).
In order to detect a dosing effect of rituximab exposure on SPM risk, we focused the analysis on the schedule of administration (first line versus relapse) and the length of administration (no maintenance versus maintenance). Induction therapy with rituximab randomization in first line (MINT, LNH98.5, IESLG19, RICOVER60, OSHO#39) was not associated with an increased risk of SPM when compared with induction therapy with rituximab randomization in a relapse setting (CORAL, EORTC 20 981) (P = 0.87). Rituximab use over prolonged periods, as in maintenance (PRIMA, EORTC 20981, SAKK35/98, CORAL), did not modify SPM risk compared with rituximab use in induction therapy without maintenance (MINT, LNH98.5, IESLG19 RICOVER60) (P = 0.87). Cumulative exposure through prolonged administration did not contribute to an increased risk of SPM (P = 0.86).
discussion
Rituximab has substantially improved the outcome of patients with CD20+ B-cell NHL. Patients in the trials analyzed had been exposed to rituximab between 1998 and 2008, which corresponds to the FDA rituximab approval in 1997. With a median follow-up of 73 months, we did not detect any increased risk of SPM among the 4621 patients treated in 9 trials that randomly assessed the benefit of rituximab in such patients. Our systematic review excluded 15 trials on the basis that SPM occurrence or related death according to rituximab exposure was not explicitly reported in the original publication. Among these, a trial reported by Petengell in 2013 evaluated 280 rituximab-naive patients with relapsed FL who achieved either complete or very good partial remission with salvage chemotherapy [26] . Patients were randomly assigned using a factorial design to rituximab purging (375 mg/m 2 once per week for 4 weeks) before BEAM therapy supported by an autologous stem cell transplant and to maintenance rituximab (375 mg/m 2 once every 2 months for four infusions). At a median follow-up of 8.3 years, SPMs were reported in 11 patients who died at intervals ranging from 9 months to 8 years after random assignment. Despite no reported difference in SPM between treatment arms, specific numbers and their relative exposure to rituximab were required for our analysis. These findings remain in agreement with our results.
Rituximab dosing was the same for all analyzed trials and represented the standard dosing of 375 mg/m 2 per infusion. Since the rituximab effect is presumed to be transient, we investigated a dose-effect through the length of time exposed. No increased risk of SPM could be detected in patients exposed for periods longer than 8 months, as in maintenance regimen (n = 4), when compared with patients exposed for shorter period (n = 5). Benefit of rituximab maintenance in FL for OS has been reported in a Cochrane database systematic review updated in 2011 (HR: 0.60, 95% CI 0.45-0.79) [27] . The analysis of 2586 patients from 6 trials demonstrated an OS benefit irrespective of the maintenance schedule. The rate of grade III/IV adverse events was also analyzed. This rate was reported in two trials and was noticed higher with rituximab Annals of Oncology reviews maintenance therapy (RR 1.52, 95% CI 1.00-2.30), without detailed data on SPM. In our analysis, rituximab maintenance was not associated with an increased risk of SPM. The limited follow-up and the number of patients and events in our metaanalysis may be, however, insufficient to detect a small effect. Noteworthy, patients exposed to rituximab maintenance after an HDT followed by autologous stem cell transplants are not considered at increased risk of SPM as reported in two trials [26, 28] . Although a sex-dependent effect and the higher weight of males contribute to their faster rituximab clearance [29] , no increased risk of SPM has been detected among women (n = 1078) relative to men (n = 1164).
SPM occurrence was not increased among patients treated for refractory or relapsing NHL. A Cochrane database systematic review evaluated the addition of rituximab to chemotherapy among 1943 patients with indolent NHL or MCL treated in first line or with refractory or progressive disease [6] . A pooled analysis of these patients from seven trials yielded an HR for death from any cause of 0.65 (95% CI 0.54-0.78), without specific data of SPM.
In conclusion, there was no evidence that rituximab may predispose to SPM in our meta-analysis of 9 published trials randomizing 4621 patients with a median follow-up of 73 months. Prolonged survival associated with emergent therapies in NHL warrants long-term surveillance and reporting of SPM among survivors. 
